Filing Details
- Accession Number:
- 0000899243-21-032755
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-12 16:20:57
- Reporting Period:
- 2021-08-10
- Accepted Time:
- 2021-08-12 16:20:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1680581 | Fulcrum Therapeutics Inc. | FULC | Pharmaceutical Preparations (2834) | 474839948 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1843784 | Christopher Moxham | C/O Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge MA 02139 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-10 | 20,714 | $7.84 | 20,714 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-08-10 | 20,714 | $17.00 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-08-10 | 31,071 | $7.84 | 31,071 | No | 4 | M | Direct | |
| Common Stockm | Disposition | 2021-08-10 | 31,071 | $18.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-08-10 | 20,714 | $0.00 | 20,714 | $7.84 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-08-10 | 31,071 | $0.00 | 31,071 | $7.84 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 103,572 | 2029-01-21 | No | 4 | M | Direct | |
| 72,501 | 2029-01-21 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021.
- The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.
Billionaire Hedge Funds
